Valuation: BioRestorative Therapies, Inc.

Market Cap 9.43M 8.25M 7.62M 7.12M 13.39M 891M 13.7M 91.7M 35.4M 440M 35.4M 34.63M 1.53B P/E 2026 *
-0.75x
P/E 2027 * -0.91x
Enterprise Value 9.43M 8.25M 7.62M 7.12M 13.39M 891M 13.7M 91.7M 35.4M 440M 35.4M 34.63M 1.53B EV / Sales 2026 *
6.71x
EV / Sales 2027 * 4.08x
Free-Float
87.87%
Yield 2026 *
-
Yield 2027 * -
1 day+0.11%
1 week-9.54%
Current month-22.59%
1 month-22.59%
3 months+24.50%
6 months-66.36%
Current year-68.51%
1 week 0.36
Extreme 0.3616
0.43
1 month 0.32
Extreme 0.32
0.5
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
4.6
5 years 0.16
Extreme 0.1593
32
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 55 16/11/2020
Director of Finance/CFO 59 04/11/2021
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 16/11/2020
Director/Board Member 60 29/10/2021
Director/Board Member 28 12/06/2026
Date Insider Type Main position Quantity % Market Cap.
06/10/25Free

Chief Executive Officer

27,344 0.3427%
06/10/25Free

Chief Technology Officer

23,438 0.2938%
14/02/25Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%-9.54%-77.02%-91.33% 9.43M
+2.83%-0.71%+71.82%+127.12% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
+3.33%+4.51%-11.68%-11.91% 23.84B
+1.32%+6.22%+5.28%+415.45% 22.7B
+6.53%+6.99%+39.01%-29.15% 16.12B
-0.89%+5.71%+24.30%+186.29% 13.64B
+9.96%+15.98%+157.65%+310.89% 14.8B
+2.85%+2.81%+75.32%+139.44% 12.16B
+6.17%+10.22%+163.15%+166.44% 11.85B
Average +3.89%+5.71%+53.95%+131.73% 22.66B
Weighted average by Cap. +4.37%+7.70%+66.61%+142.88%

Financials

2026 *2027 *
Net sales 1.4M 1.23M 1.14M 1.06M 2M 133M 2.04M 13.67M 5.28M 65.53M 5.28M 5.16M 228M 2.31M 2.02M 1.87M 1.75M 3.29M 219M 3.36M 22.49M 8.68M 108M 8.68M 8.49M 374M
Net income -13.52M -11.84M -10.93M -10.21M -19.22M -1.28B -19.65M -132M -50.78M -631M -50.79M -49.67M -2.19B -15.56M -13.62M -12.58M -11.74M -22.11M -1.47B -22.61M -151M -58.43M -726M -58.43M -57.15M -2.52B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
29/06/26 US$0.3700 +0.11% 259,226
26/06/26 US$0.3696 -6.19% 293,900
25/06/26 US$0.3940 -0.81% 1,057,095
24/06/26 US$0.3972 +3.60% 505,699
23/06/26 US$0.3834 -6.26% 300,759
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3700USD
Average target price
8.000USD
Spread / Average Target
+2,062.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock